Baker Brian Lee 4

Accession 0001209191-21-022949

CIK 0001595893other

View on SEC.gov Company Profile

Filed

Mar 23, 8:00 PM ET

Accepted

Mar 24, 9:54 PM ET

Size

34.2 KB

Accession

0001209191-21-022949

Insider Transaction Report

Form 4

Period: 2021-03-22

Turning Point Therapeutics, Inc.TPTX

Baker Brian Lee

VP of Finance and Admin.

Transactions

Exercise/Conversion
Common Stock
2021-03-23$2.19/sh+11,904$26,070→ 16,020 total
Sale
Common Stock
2021-03-23$98.76/sh−4,459$440,371→ 23,173 total
Sale
Common Stock
2021-03-23$102.23/sh−8,061$824,076→ 8,106 total
Exercise/Conversion
Stock Option (right to buy)
2021-03-23−11,904→ 2,165 total
Exercise: $2.19Exp: 2027-08-08→ Common Stock (11,904 underlying)
Exercise/Conversion
Common Stock
2021-03-23$5.12/sh+4,545$23,270→ 21,863 total
Sale
Common Stock
2021-03-23$100.98/sh−5,010$505,910→ 16,167 total
Exercise/Conversion
Common Stock
2021-03-23$3.20/sh+1,298$4,154→ 17,318 total
Exercise/Conversion
Stock Option (right to buy)
2021-03-23−1,298→ 0 total
Exercise: $3.20Exp: 2028-03-08→ Common Stock (1,298 underlying)
Exercise/Conversion
Stock Option (right to buy)
2021-03-23−10,688→ 19,668 total
Exercise: $7.43Exp: 2029-02-19→ Common Stock (10,688 underlying)
Sale
Common Stock
2021-03-23$100.07/sh−1,996$199,740→ 21,177 total
Sale
Common Stock
2021-03-23$102.84/sh−3,890$400,048→ 4,216 total
Exercise/Conversion
Stock Option (right to buy)
2021-03-23−4,545→ 6,494 total
Exercise: $5.12Exp: 2028-11-05→ Common Stock (4,545 underlying)
Award
Common Stock
2021-03-22+1,625→ 4,116 total
Exercise/Conversion
Common Stock
2021-03-23$7.43/sh+10,688$79,412→ 32,551 total
Sale
Common Stock
2021-03-23$97.89/sh−4,919$481,521→ 27,632 total
Sale
Common Stock
2021-03-23$104.17/sh−100$10,417→ 4,116 total

Footnotes (12)

[F1]Represents restricted stock unit award granted under the Issuer's 2019 Equity Incentive Plan.
[F10]Vests in 36 equal successive monthly installments on each monthly anniversary of January 1, 2018.
[F11]1/48th of the shares vest monthly following November 6, 2018.
[F12]25% of the shares vest on February 12, 2020 and 1/48th of the shares vest monthly thereafter over the next three years.
[F2]Reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted by the Reporting Person on November 16, 2020.
[F3]The weighted average sale price for the transaction reported was $97.89, and the range of prices were between $97.34 and $98.315. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
[F4]The weighted average sale price for the transaction reported was $98.76, and the range of prices were between $98.40 and $99.29. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
[F5]The weighted average sale price for the transaction reported was $100.07, and the range of prices were between $99.56 and $100.56. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
[F6]The weighted average sale price for the transaction reported was $100.98, and the range of prices were between $100.57 and $101.54. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
[F7]The weighted average sale price for the transaction reported was $102.23, and the range of prices were between $101.62 and $102.605. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
[F8]The weighted average sale price for the transaction reported was $102.84, and the range of prices were between $102.64 and $103.21. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
[F9]One-fourth of the option vested on July 6, 2018. Thereafter, 1/48th of the Option vests on a monthly basis over 36 months until the option becomes fully vested.

Documents

1 file

4
doc4.xmlPrimary
FORM 4 SUBMISSION

Issuer

Turning Point Therapeutics, Inc.

CIK 0001595893

→

Entity typeother

Related Parties

filerCIK 0001772399

Filing Metadata

Form type: 4
Filed: Mar 23, 8:00 PM ET
Accepted: Mar 24, 9:54 PM ET
Size: 34.2 KB

View on SEC.gov